An observational study in Bladder Cancer, sponsored by Peking University First Hospital. Completed at 1 site in China. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Peking University First Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.
Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 51st largest by enrollment of the 53 observational ones that give a count, is one of 25 that started in 2021, is one of 53 observational ones, and was the 166th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
Yunnan Cancer Hospital · Sites in China
Ages 18–80
AstraZeneca · Sites in China, United States, Australia and 13 more countries
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in China, United States, Argentina and 14 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 62 · Phase 3 24 · Phase 4 2
First in 2008; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 200 across 412 observational studies indexed under Urinary Bladder Neoplasms.
Median enrollment 75 across the 141 interventional studies, 266 across the 53 observational. Of the 40 that completed or were terminated, 8 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 194 have an industry lead sponsor. The 10 most frequent:
Peking University First Hospital is the lead sponsor of 392 studies on the registry; 187 are open to participants now.
Peking University First Hospital has 6 studies filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Urinary Bladder Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT06364904Phase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityA Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | 2027-04-15 |
| NCT05531123Fudan UniversityRisk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer | 2026-12 |
| NCT06972771Yunnan Cancer HospitalTrop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer | 2026-12-30 |
| NCT05975307Sun Yat-sen UniversityTreating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation | 2026-12-31 |
Add all 31 to your calendar (.ics) → With an account.
Among the 194 studies in Urinary Bladder Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this ambispective cohort study is to evaluate the safety and palliative efficacy of a dose-escalated stereotactic ablative radiotherapy (SABR) protocol in ultra-elderly patients (age > 75) with medically inoperable bladder cancer. This study combines a retrospective analysis of early clinical cases with a prospective observation of subsequent patients treated under the same institutional protocol.
The main questions it aims to answer are:
Participants in this cohort:
The study population consists of ultra-elderly patients (aged >75 years) diagnosed with biopsy-confirmed urothelial carcinoma of the bladder (T2-T4N0M0). These participants were candidates for palliative radiotherapy due to being medically inoperable or unwilling to undergo radical cystectomy. The cohort includes 16 consecutive patients following a standardized institutional dose-escalation protocol. The population is divided into a retrospective cohort (the first 10 patients) and a prospective cohort (the subsequent 6 patients), all of whom met identical clinical inclusion criteria to ensure data consistency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Level 1: 30 Gy in 5 Fractions
Radiation: Dose Level 1
Dose Level 2: 35 Gy in 5 Fractions
Radiation: Dose Level 2
Dose Level 3: 37.5 Gy in 5 Fractions
Radiation: Dose Level 3
Dose Level 4: 40 Gy in 5 Fractions
Radiation: Dose Level 4
Dose Level 1: 30 Gy in 5 Fractions
Dose Level 2: 35 Gy in 5 Fractions
Dose Level 3: 37.5 Gy in 5 Fractions
Dose Level 4: 40 Gy in 5 Fractions
Maximum tolerated dose (MTD) of five-fraction SABR
Description: The MTD is the highest dose level at which no more than one of three, or one of six, participants has a dose-limiting toxicity (DLT). A DLT is any radiotherapy-related adverse event of Grade 3 or higher (NCI CTCAE v5.0) occurring within 7 months after completion of SABR.
Time frame: Up to 7 months after completion of SABR
Acute radiotherapy-related toxicity
Number of participants with radiotherapy-related adverse events graded with NCI CTCAE v5.0, from the start of SABR to 3 months after completion of SABR.
Time frame: Up to 3 months after completion of SABR
Late radiotherapy-related toxicity
Number of participants with radiotherapy-related adverse events graded with NCI CTCAE v5.0, occurring more than 3 months after completion of SABR
Time frame: From 3 months to 24 months after completion of SABR
Symptomatic response rate
The percentage improvement in cancer-related symptoms (hematuria, frequency, dysuria)
Time frame: At 3-month intervals, assessed up to 24 months
Local recurrence (LR)
defined as an enlarging lesion within the PTV defined by RECIST 1.1 criteria
Time frame: At 3-month intervals, assessed up to 24 months
Overall Survival (OS)
Overall survival is defined as the time from the date of the first fraction of SABR to the date of death from any cause. For patients who remain alive at the time of the last follow-up, survival time will be censored at the date of the last contact.
Time frame: From the start of SABR treatment until the date of death or last follow-up (assessed up to 2 years).
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Sep 2025, 45 months.
Of 168 non-industry observational studies under Urinary Bladder Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30. This study's 45 months is below that.
Counting every sponsor, half of 203 studies reached it within 58 months; a quarter within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital →